Confirmation of Visual Field Abnormalities in the Ocular Hypertension Treatment Study

Abstract

THE OCULAR Hypertension Treatment Study (OHTS) is a multicenter trial, funded by the National Eye Institute, National Institutes of Health, Bethesda, Md. The OHTS seeks to evaluate the safety and efficacy of topical ocular hypotensive medication in preventing or delaying the onset of visual field loss, optic nerve damage, or both in patients with ocular hypertension who are at moderate risk for developing primary open-angle glaucoma.^1,2 Half of the patients receive topical ocular hypertensive medication, and half receive careful observation only. Automated static perimetry (Humphrey field analyzer program 30-2 full-threshold test; Humphrey Systems, Dublin, Calif) is used as one of the primary outcome measures for the OHTS.¹ Progressive glaucomatous cupping, as determined from optic disc photographs, is also a primary outcome measurement for the OHTS.^1,2 A detailed description of the OHTS protocol is available elsewhere.^1,2